medcac impress interest
ahead ew earn releas updat ew
sales/ep estim cc cc ex-royalti
cc cc ex-royalti
exhibit estim compar consensu
 manag sales/ep guidanc rang
forecast gm/om/tax vs prior
cardioband tavr forecast yoy
basi factset consensu yoy report
yoy report note forecast exclud
buy us royalti eu cardioband sale
factset us/ ou tavr consensu contain mix estim includ
 exclud royalties/cardioband model us tavr market
ex-royalti growth ou market growth cc
bake conservat ex-u tavr given delay centera ultra
updat estim updat fy ew sales/ep
estim cc cc ex-royalti report
cc cc ex-royalti report
exhibit decreas revenu mostli due neg
fx impact lower ou thvt centera hiccup ultra delay
slightli off-set higher us thvt critic estim compar
consensu manag sales/
ep guidanc forecast gm/om/tax
unchang model thvt cc growth
in-lin higher end manag guidanc rang
look ahead expect buoyanc ww tavr
market cc growth ew share posit strengthen
centera ex-u ultra ww
look call us/ou tavr market growth share
given encourag earli result continu pg
tr target
progress centera re-launch eu includ feedback design alter enhanc
deliveri system prospect share gains/pric resist centera ultra in-plac
updat european us launch time sapien ultra thought follow
medcac tavr panel link vi balanc struck access outcom variabl
potenti impact us therapi adopt
ew earn call juli pm et dial-in
valuat risk price target sum assign base busi
inclus tavr associ mitral/tricuspid adjac base busi dcf
assum ew tavr overal sale ex-mitral/tricuspid
unburden invest structur heart adjac presum oper margin
base busi thusli defin employ discount rate termin growth rate
presum develop non-thvt growth driver mitral/tricuspid consid
termin valu contribut combin segment assum market
ew hold share associ oper margin point time discount
rate termin growth rate given larger patient size mitral/tricuspid adjac
interven trans-cathet learn tavr off-set increas technical/clin
uncertainti dont feel market assumpt year henc unreason
like take tavr year achiev sale trans-cathet mitral sale alreadi total
dont assign valu mitral/tricuspid posit cash flow prior
consider drag invest period princip risk thesi includ
over-estim address aortic mitral tricuspid preval pool technical/clin
uncertainti mitral/tricuspid heighten competit thvt higher expect thvt
page
page
page
page
million except per share surgeri expens inc interest incom adjust analysisnon-tavi gross gross gross sg sg sg analysistot sale sale cc cc ex cc incl cc incl cardioband vasc forma corpor
edward lifesci corp focus technolog treat structur heart diseas
critic ill patient design develop manufactur market product treat cardiovascular
diseas product technolog categor three area surgic heart valv therapi
transcathet heart valv critic surgic heart valv therapi portfolio includ
tissu heart valv heart valv repair product surgic replac repair patient
heart valv transcathet heart valv portfolio includ technolog design treat heart
valv diseas use catheter-bas approach oppos open surgic techniqu critic
portfolio product includ pulmonari arteri cathet dispos pressur transduc
advanc monitor system found mile lowel edward
headquart irvin ca
invest thesi ew remain unchang princip driven share posit tavr
market exceed link similar size mitral tricuspid opportun
circa catalyt basi believ low risk tavr trial provid bump
ww tavr market cc growth versu part due increas surgic
cannib link ew share posit hold firm due combin effect centera
ex-u sapien ultra ww uptick market momentum like help allay concern held
regard size underli preval pool also feel cours
investor attent becom reliabl focus mitral tricuspid adjac
preval us mitral/tricuspid patient versu aortic stenosi patient link
valuat risk
price target sum assign base busi inclus tavr
associ mitral tricuspid adjac base busi dcf assum
ew tavr overal sale ex-mitral/tricuspid unburden invest
structur heart adjac presum oper margin base busi
thusli defin employ discount rate termin growth rate presum
develop non-thvt growth driver mitral tricuspid consid termin valu
contribut combin segment assum market ew hold
share associ oper margin point time discount rate
termin growth rate given larger patient size mitral/tricuspid adjac interven
trans-cathet learn tavr off-set increas technical/clin uncertainti
dont feel market assumpt year henc unreason like take tavr
year achiev sale trans-cathet mitral sale alreadi total
dont assign valu mitral/tricuspid posit cash flow prior consider
drag invest period
princip risk thesi includ over-estim address aortic mitral tricuspid
preval pool technic clinic uncertainti mitral/tricuspid heighten competit
thvt higher expect thvt price pressur
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
